SM
ESPR

Sabby Management’s Esperion Therapeutics ESPR Stock Holding History

Sabby Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,179
Closed -$735K – 104
2022
Q4 		$735K Buy
1,179
+999
+555% +$7.14K 0.64% 20
2022
Q3 		$121K Buy
+180
New +$1.24K 0.15% 75
2019
Q1 		– Sell
-8,467
Closed -$38.9M – 98
2018
Q4 		$38.9M Buy
8,467
+1,775
+27% +$85.5K 8.57% 3
2018
Q3 		$29.7M Sell
6,692
-296
-4% -$13.6K 3.8% 6
2018
Q2 		$27.4M Buy
6,988
+935
+15% +$47.2K 4.23% 8
2018
Q1 		$43.8M Buy
6,053
+4,383
+262% +$322K 5.21% 5
2017
Q4 		$11M Buy
1,670
+191
+13% +$10.3K 1% 20
2017
Q3 		$7.41M Buy
1,479
+1,222
+475% +$58.9K 0.48% 28
2017
Q2 		$1.19M Hold
257
– – 0.08% 96
2017
Q1 		$907K Buy
+257
New +$5.88K 0.05% 136
2015
Q3 		– Sell
-399
Closed -$3.26M – 389
2015
Q2 		$3.26M Buy
+399
New +$39.1K 0.12% 123

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Sabby Management's ESPR Position: Q1 2022 in Review

Sabby Management sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 940,400 shares — an estimated $4.03M sold.

Sabby Management first reported a position in ESPR in Q1 2015 and held it in 10 quarters. The position peaked at $9.36M in Q4 2017. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Sabby Management reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 940,400 Esperion Therapeutics shares in Q1 2022, an estimated $4.03M.
  • Sabby Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 10 quarters.
  • Sabby Management's Esperion Therapeutics position peaked at $9.36M in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.